GCK
Hexokinase-4
As of the edition of 20 October 2026, GCK (hexokinase-4, UniProt P35557) has 8 drugs tested at it and 8 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35557
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 35
- Disease areas
- Hormones; Nutrition and metabolism; Immune system; Pregnancy and women's health; Urinary and reproductive; Cancer; Digestive system; Infections
- Registered trials of its drugs
- 87
Drugs at this target
| Status | Count |
|---|---|
| Active | 3 |
| Went quiet | 4 |
| Stopped | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| AZD-1656 | Active | Phase 2 | none listed |
| Dorzagliatin | Active | Phase 4 | none listed |
| Mk-0941 free base | Stopped | Phase 2 | none listed |
| Nerigliatin | Went quiet | Phase 2 | none listed |
| PF-04991532 | Went quiet | Phase 2 | none listed |
| LY-2608204 | Went quiet | Phase 2 | none listed |
| Cadisegliatin | Active | Phase 3 | none listed |
| AZD6370 | Went quiet | Phase 1 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Engaged | 3 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Eli Lilly | Route A |
| Merck & Co. | Route A |
| Pfizer | Route A |
The other 5 companies at GCK
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at GCK, ranked, with the facts behind eachRequest access. Nothing is shown until you do.